This brand name is authorized in United States
The drug JESDUVROQ contains one active pharmaceutical ingredient (API):
1
Daprodustat
UNII JVR38ZM64B - DAPRODUSTAT
|
Daprodustat is indicated for the treatment of anemia due to chronic kidney disease. Daprodustat is a reversible inhibitor of HIF-PH1, PH2 and PH3 (IC50 in the low nM range). This activity results in the stabilization and nuclear accumulation of HIF-1α and HIF-2α transcription factors, leading to increased transcription of the HIF-responsive genes, including erythropoietin. |
Below package inserts are available for further reading:
Title | Information Source | Document Type | |
---|---|---|---|
JESDUVROQ Film coated tablet | FDA, National Drug Code (US) | MPI, US: SPL/PLR |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
ATC code | Group title | Classification |
---|---|---|
B03XA07 | B Blood and blood forming organs → B03 Antianemic preparations → B03X Other antianemic preparations → B03XA Other antianemic preparations | |
This drug has been assigned below unique identifiers within the countries it is being marketed:
Country | Identification scheme | Identifier(s) |
---|---|---|
Country: US | FDA, National Drug Code | Identifier(s): 0173-0897, 0173-0903, 0173-0906, 0173-0911, 0173-0914 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.